-
Areas
Technologies
  • Clinical trials
  • Cohort studies
  • Cohort analysis

About

There are five clear areas of focus for the translational research undertaken by the Gibbs Lab.

* We lead national and international cancer registries that capture comprehensive patient, tumour, treatment and outcome data for all major solid cancers. This data is used to enable audit and research, including supporting the novel concept of registry based clinical trials in oncology collection and translational research by combining data and tissue based research.

* More recently the Gibbs Lab have partnered with the Victorian Comprehensive Cancer Centre (VCCC) to undertake a number of registry-based trials. This work is ongoing with a number of new trial designs under review for inclusion as we expand the portfolio to different modalities of treatment of patients with cancer

* We lead multiple international randomised trials to define the potential of ctDNA as a marker of minimal residual disease to determine recurrence risk and to optimise adjuvant therapy.

* We have initiated studies of patient derived tumour organoids, with the ultimate aim of in vitro sensitivity testing being used to guide clinical treatment selection.

* Clinical Trials working with cooperative groups such as the AGITG and others to provide all aspects of clinical trial start up, initiation, study management to data analysis and close out.

Each program is led by a medical oncologist with appropriate sub-speciality expertise and substantial clinical appointments, with the ultimate focus being clinical relevance and impact.

Publications

Selected publications from Prof Peter Gibbs

Gibbs P, Abubaker K, Wang D, Feng Z, Hamad J, Liao J, Stroh C, Vlassak S, Heinrich K, Khattak A, Scheuenpflug J. Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC. Clinical Colorectal Cancer. 2025;24(3):10.1016/j.clcc.2025.03.004

McKenzie J, Wong V, Mendis S, Wong R, Kosmider S, To YH, Nott L, Shapiro J, Torres J, Lee B, Jalali A, Lim SH-S, Caird S, Khattak A, Gibbs P. Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 2025;24(3):10.1016/j.clcc.2025.04.001

Curtis SD, Panda S, Li A, Xu H, Bai Y, Ogihara I, O’Reilly E, Wang Y, Dobbyn L, Popoli M, Ptak J, Nehme N, Silliman N, Tie J, Gibbs P, Ho-Pham LT, Tran BNH, Tran TS, Nguyen TV, Irajizad E, Goggins M, Wolfgang CL, Wang T-L, Shih I-M, Fader A, Lennon AM, Hruban RH, Bettegowda C, Gilbert L, Kinzler KW, Papadopoulos N, Vogelstein B, Vogelstein JT, Douville C. Minimizing and quantifying uncertainty in AI-informed decisions: Applications in medicine. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(34):10.1073/pnas.2424203122

Curtis SD, Liu T, Bai Y, Wang Y, Panda S, Li A, Xu H, O’Reilly E, Dobbyn L, Popoli M, Ptak J, Silliman N, Thoburn C, Tie J, Gibbs P, Ho-Pham LT, Tran BNH, Tran TS, Nguyen TV, Konig MF, Petri M, Rosen A, Mecoli CA, Shah AA, Mulder F, van Es N, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein JT, Vogelstein B, Douville C, Klok FA, Beyer-Westendorf J, Jara-Palomares L, Ageno W, Peters MJL, Delluc A, Best M, Guman N, Otten H-M, Mulder F, van Es N. Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(34):10.1073/pnas.2426890122

Drosdowsky A, Lamb KE, Marvelde LT, Gibbs P, Dunn C, Faragher I, Jones I, IJzerman MJ, Emery JD. Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study. International Journal of Cancer. 2025;157(4):10.1002/ijc.35414

McNeil JJ, Tonkin AM, Newman AB, Williamson JD, Woods RL, Chan AT, Donnan GA, Reid CM, Nelson MR, Espinoza SE, Abhayaratna WP, Shah RC, Gibbs P, Ernst ME, Stocks NP, Beilin LJ, Kirpach B, Ryan J, Wolfe R, Murray AM, Margolis KL. From the ASPREE investigators: Response to Wittes et al.Clinical Trials. 2025;22(4):10.1177/17407745251344560

Theis M, Hong W, Lee B, Nowak S, Luetkens J, Stuckey S, Gibbs P, Thomson B, Michael M, Sprinkart AM, Ko HS. Skeletal muscle and visceral fat density are predictive imaging biomarkers for overall survival in patients with pancreatic adenocarcinoma: A retrospective multicenter analysis. Surgical Oncology. 2025;61:10.1016/j.suronc.2025.102251

Zaman FY, Orchard SG, Polekhina G, Gibbs P, Bernstein WB, Macrae F, Tie J, Millar J, Gately L, Rodríguez LM, van Londen GJ, Mar V, Hiscutt E, Adler N, Kent A, Ong WL, Haydon A, Warner E, Chan AT, Zalcberg J. Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. Journal of the National Cancer Institute. 2025;:10.1093/jnci/djaf145

Luk IY, Mooi JK, Mouradov D, Tan T, Scott CM, Chionh F, Jenkins LJ, Reehorst CM, Nightingale R, Savas P, Tse JW, Crake RL, Batlle E, Arango D, Dopeso H, Gibbs P, Tebbutt NC, Luwor RB, Scott AM, Basheer F, Dhillon AS, Clemons NJ, Williams DS, Firestein R, Sieber OM, Mariadason JM. Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines. Communications Biology. 2025;8(1):10.1038/s42003-025-08251-0

Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.